

Global Hepatitis Drug Market & Clinical Trials Insight 2023

<https://marketpublishers.com/r/G51B00CBBA4EN.html>

Date: June 2017

Pages: 550

Price: US\$ 2,400.00 (Single User License)

ID: G51B00CBBA4EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Hepatitis Drug Market & Clinical Trials Insight 2023” report gives comprehensive insight on various clinical and non-clinical advancements in the global Hepatitis drug market. Currently, there are 321 Hepatitis drugs in clinical pipeline and 110 Hepatitis drugs are commercially available in the market. Hepatitis drug clinical trials landscape is dominated by Hepatitis C drug with 145 drugs in various phases of development and 25 drugs commercially available in the market. The overall Hepatitis drug revenues are expected to surpass US\$ 70 Billion by 2023 with major share accounted by Hepatitis C drugs.

“Global Hepatitis Drug Market & Clinical Trials Insight 2023” report highlights:

Prevalence of Hepatitis Infection

Available Drug Classes for Hepatitis Drug

Global Hepatitis Drug Market Analysis

Global Hepatitis (A,B,C,D & E) Drug Clinical Pipeline Insight

Marketed Hepatitis Drug Clinical Insight by Drug Class

Future Perspective of Hepatitis Therapeutics

Hepatitis virus infection lies among primary public health threats globally and is basically a main reason for the development of liver cirrhosis and hepatocellular carcinoma. The incidence and prevalence of hepatitis viral infection is growing and increases the burden. However, the worldwide remains unknown due to heterogeneous registration and case definitions. There are several subcategories of viruses which cause the infection or inflammation to liver and these subgroups are hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus and hepatitis E virus. The investigation for other subcategory of viruses is ongoing. Hepatitis B virus and hepatitis C virus are main leading causes of liver diseases.

The past two decades have witnessed substantial progress in the treatment of hepatitis virus infection and it includes the introduction of nucleotides and nucleoside analogues, interferons, toll like receptors and protease inhibitors which revolutionized the hepatitis disease management.

With the recent dramatic progress in development of potent antiviral drugs for chronic hepatitis virus infection, virological responses are achievable in almost all patients. Most clinical practice guidelines strongly recommended the treatment of patients with antiviral agents if they have proper indications. The main aim of antiviral treatment is to inhibit the hepatitis virus replication and improve the liver pathology but it rarely cures chronic hepatitis infection.

The global hepatitis drug market is expected to surpass USD 70 Billion by 2023 with the rising number of infected population, growing consumption of alcohol and drugs and the improvement in the access to hepatitis medicines. The introduction of generic drugs of hepatitis has also changed the market dynamics across the globe. With the increase of people being able to afford the generic versions, the usage rates of drugs are expected to grow rapidly over the next few years.

Contents

1. INTRODUCTION TO HEPATITIS DISEASE

1.1 Prologue

1.1.1 History of Hepatitis

1.1.2 Causes of Hepatitis Disease

1.2 Types of Viruses which are Responsible for Hepatitis Disease

2. GLOBAL PREVALENCE OF HEPATITIS INFECTION

3. AVAILABLE DRUG CLASSES FOR HEPATITIS DISEASE TREATMENT

3.1 Interferon Alfa Therapy

3.2 Protease Inhibitors Therapy

3.3 Polymerase Inhibitors Therapy

3.4 Toll like Receptor Agonists Therapy

4. GLOBAL HEPATITIS DRUG MARKET ANALYSIS

4.1 Introduction

4.2 Global Hepatitis Drug Market Insight

5. GLOBAL HEPATITIS DRUG MARKET DYNAMICS

5.1 Favorable Market Parameters

5.2 Market Challenges

6. FUTURE PERSPECTIVE OF HEPATITIS THERAPEUTICS

7. GLOBAL HEPATITIS DRUG CLINICAL PIPELINE OVERVIEW

7.1 Hepatitis A

7.2 Hepatitis B

7.3 Hepatitis C

7.4 Hepatitis D

7.5 Hepatitis E

8. HEPATITIS A DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (5

DRUGS)

- 8.1 Research
- 8.2 Preclinical
- 8.3 Clinical
- 8.4 Phase-III

9. MARKETING HEPATITIS A DRUG CLINICAL INSIGHT BY DRUG CLASS (12 DRUGS)**10. HEPATITIS B DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (134 DRUGS)**

- 10.1 Unknown
- 10.2 Research
- 10.3 Preclinical
- 10.4 Clinical
- 10.5 Phase-I
- 10.6 Phase-I/II
- 10.7 Phase-II
- 10.8 Phase-II/III
- 10.9 Phase-III
- 10.10 Preregistration
- 10.11 Registered

11. MARKETING HEPATITIS B DRUG CLINICAL INSIGHT BY DRUG CLASS (46 DRUGS)**12. HEPATITIS C DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (145 DRUGS)**

- 12.1 Unknown
- 12.2 Research
- 12.3 Preclinical
- 12.4 Clinical
- 12.5 Phase-I
- 12.6 Phase-I/II
- 12.7 Phase-II
- 12.8 Phase-II/III

- 12.9 Phase-III
- 12.10 Preregistration
- 12.11 Registered

13. MARKETING HEPATITIS C DRUG CLINICAL INSIGHT BY DRUG CLASS (25 DRUGS)

- 13.1 ZEPATIER
- 13.2 Harvoni
- 13.3 Victrelis
- 13.4 Copegus
- 13.5 Sovaldi
- 13.6 Vanihep
- 13.7 Incivek
- 13.8 Olysio
- 13.9 VIEKIRA
- 13.10 Infergen
- 13.11 Viekirax
- 13.12 Epclusa
- 13.13 Ximency
- 13.14 Daclatasvir + Asunaprevir Combination
- 13.15 Peginterferon Alfa-2b (Y-shaped pegylation)
- 13.16 Golotimod
- 13.17 Algeron
- 13.18 Pegatron
- 13.19 Rebetron
- 13.20 IBAVYR
- 13.21 Reiferon Retard
- 13.22 Reiferon - Interferon Alpha-2a Biosimilar
- 13.23 Interferon Alpha-2a
- 13.24 Glycyron Tablets
- 13.25 Daklinza

14. HEPATITIS D DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (4 DRUGS)

- 14.1 Research
- 14.2 Preclinical
- 14.3 Phase-II

15. HEPATITIS E DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (2 DRUGS)

15.1 Preclinical

15.2 Phase-I

16. MARKETING HEPATITIS E DRUG CLINICAL INSIGHT BY DRUG CLASS (1 DRUG)

17. MULTIPLE HEPATITIS DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (31 DRUGS)

17.1 Unknown

17.2 Research

17.3 Preclinical

17.4 Clinical

17.5 Phase-I

17.6 Phase-I/II

17.7 Phase-II

17.8 Preregistration

18. MARKETING MULTIPLE HEPATITIS DRUG CLINICAL INSIGHT BY DRUG CLASS (26 DRUGS)

19. COMPETITIVE LANDSCAPE

19.1 Arbutus Biopharma

19.2 Biostar Pharmaceuticals

19.3 Bristol-Myers Squibb

19.4 GlaxoSmithKline

19.5 Gilead Sciences

19.6 Enanta

19.7 Achillion

19.8 Presidio

19.9 Benitec Biopharma

19.10 Janssen Pharmaceuticals

19.11 AbbVie

19.12 Merck

19.13 Novira Therapeutics

19.14 Contravir

19.15 VBI Vaccines

List Of Figures

LIST OF FIGURES

Figure 1-1: Pathogenesis of Liver by the Exposure of Different Factors

Figure 1-2: Historical Development of Hepatitis Drug Treatment

Figure 1-3: Factors which are Responsible for Hepatitis Disease Development

Figure 2-1: Global - Incidence & Mortality Cases of Hepatitis B Infection (Million), 2015

Figure 2-2: Global - Incidence & Mortality Cases of Hepatitis C Infection (Million), 2015

Figure 3-1: Interferon Alpha - Mechanism of Action for Treating Liver Disease

Figure 3-2: Toll like Receptors & Activation of Antiviral Innate and Adaptive Immune Responses in Hepatitis Virus Infection

Figure 4-1: Global- Hepatitis B & C as Cause for Liver Cancer (%)

Figure 4-2: Global - Hepatitis Drug Market (US\$ Billion), 2016 - 2023

Figure 4-3: Global- Hepatitis B Drug Market (US\$ Billion), 2016-2023

Figure 4-4: Global - Hepatitis C Drug Market (US\$ Billion), 2016-2023

Figure 5-1: Favorable Parameters to Hepatitis Drug Treatment Market Growth

Figure 5-2: Challenges to Hepatitis Therapeutic Market Growth

Figure 6-1: Future Landscape of Hepatitis Infection Treatment Research

Figure 7-1: Global - Hepatitis A Drug Clinical Pipeline by Phase (%), 2017 till 2023

Figure 7-2: Global - Hepatitis A Drug Clinical Pipeline by Phase (Number), 2017 till 2023

Figure 7-3: Global - Hepatitis B Drug Clinical Pipeline by Phase (%), 2017 till 2023

Figure 7-4: Global - Hepatitis B Drug Clinical Pipeline by Phase (Number), 2017 till 2023

Figure 7-5: Global Hepatitis C Drug Clinical Pipeline by Phase (%), 2017 till 2023

Figure 7-6: Global Hepatitis C Drug Clinical Pipeline by Phase (Number), 2017 till 2023

Figure 7-7: Global - Hepatitis D Drug Clinical Pipeline By (%), 2017 till 2023

Figure 7-8: Global - Hepatitis D Drug Clinical Pipeline by Phase (Number), 2017 till 2023

Figure 7-9: Global - Hepatitis E Drug Clinical Pipeline by Phase (%), 2017 till 2023

Figure 7-10: Global - Hepatitis E Drug Clinical Pipeline by Phase (Number), 2017 till 2023

List Of Tables

LIST OF TABLES

Table 3-1: Protease Inhibitors in Development for Hepatitis Disease Treatment

Table 3-2: Toll like Receptor Affecting Immunopathogenesis of Hepatitis Virus Infection

COMPANIES MENTIONED

Arbutus Biopharma,
Biostar Pharmaceuticals,
Bristol-Myers Squibb,
GlaxoSmithKline,
Gilead Sciences,
Enanta,
Achillion,
Presidio,
Benitec Biopharma,
Janssen Pharmaceuticals,
AbbVie,
Merck,
Novira Therapeutics,
Contravir,
VBI Vaccines

I would like to order

Product name: Global Hepatitis Drug Market & Clinical Trials Insight 2023

Product link: <https://marketpublishers.com/r/G51B00CBBA4EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G51B00CBBA4EN.html>